- Home
- FLGT vs OCS Comparison
FLGT vs OCS Comparison
Compare FLGT & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLGT
- OCS
- Stock Information
- Founded
- FLGT 2011
- OCS 2003
- Country
- FLGT United States
- OCS Switzerland
- Employees
- FLGT N/A
- OCS N/A
- Industry
- FLGT Medical Specialities
- OCS Biotechnology: Pharmaceutical Preparations
- Sector
- FLGT Health Care
- OCS Health Care
- Exchange
- FLGT Nasdaq
- OCS Nasdaq
- Market Cap
- FLGT 584.9M
- OCS 689.8M
- IPO Year
- FLGT 2016
- OCS N/A
- Fundamental
- Price
- FLGT $20.31
- OCS $19.45
- Analyst Decision
- FLGT Buy
- OCS Strong Buy
- Analyst Count
- FLGT 2
- OCS 4
- Target Price
- FLGT $24.00
- OCS $31.50
- AVG Volume (30 Days)
- FLGT 393.7K
- OCS 27.0K
- Earning Date
- FLGT 05-02-2025
- OCS 05-08-2025
- Dividend Yield
- FLGT N/A
- OCS N/A
- EPS Growth
- FLGT N/A
- OCS N/A
- EPS
- FLGT N/A
- OCS N/A
- Revenue
- FLGT $292,448,000.00
- OCS $847,333.00
- Revenue This Year
- FLGT $11.79
- OCS $53.79
- Revenue Next Year
- FLGT $10.45
- OCS $1,860.95
- P/E Ratio
- FLGT N/A
- OCS N/A
- Revenue Growth
- FLGT 1.71
- OCS N/A
- 52 Week Low
- FLGT $14.57
- OCS $10.79
- 52 Week High
- FLGT $25.11
- OCS $23.08
- Technical
- Relative Strength Index (RSI)
- FLGT 56.64
- OCS 60.16
- Support Level
- FLGT $20.03
- OCS $17.33
- Resistance Level
- FLGT $21.42
- OCS $18.90
- Average True Range (ATR)
- FLGT 0.82
- OCS 0.84
- MACD
- FLGT 0.03
- OCS 0.10
- Stochastic Oscillator
- FLGT 63.06
- OCS 97.78
About FLGT Fulgent Genetics Inc.
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.
About OCS Oculis Holding AG Ordinary shares
Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.